AR054616A1 - Tetrahidroquinolinas sustituidas - Google Patents

Tetrahidroquinolinas sustituidas

Info

Publication number
AR054616A1
AR054616A1 ARP060102412A ARP060102412A AR054616A1 AR 054616 A1 AR054616 A1 AR 054616A1 AR P060102412 A ARP060102412 A AR P060102412A AR P060102412 A ARP060102412 A AR P060102412A AR 054616 A1 AR054616 A1 AR 054616A1
Authority
AR
Argentina
Prior art keywords
naryl
nnr2
nheteroaryl
aryl
nxr
Prior art date
Application number
ARP060102412A
Other languages
English (en)
Inventor
Kai Schiemann
Ulrich Emde
Dirk Finsinger
Christiane Amendt
Nina Heiss
Frank Zenke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR054616A1 publication Critical patent/AR054616A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de formula (1), donde W es CH o N; R 1, R2, R3 independientemente entre sí, H, A, arilo, heteroarilo, Hal, -(CY2)n-SA, -(CY2)n-SCF3, -(CY2)n-SCN, -(CY2)n-CF3, -(CY2)n-OCF3, R, NR-NR2, X-(CY2)n-XR, X-(CY2)n-Y, -(CY2)n-cicloalquilo, -(CY2)n- CH=CH2, cicloalquilo, -SCH3, -SCN, -CF3, -OCF3, -OA, -(CY2)n-OH, -(CY2)n-CO2R, -(CY2)n-CN, -(CY2)n-Hal, -(CY2)n-Y, -(CY2)n-Ra, -(CY2)n-NR2, -(CY2)n-OA, -(CY2)n-OCOA, -SCF3, -(CY2)n-CONR2, -(CY2)n-NHCOA, -(CY2)n-NHSO2A, SF5, Si(CH3)3, CO-(CY2)n-CH3, - (CY2)n-N-pirrolidona, -(CH2)nNRCOOR, NRCOOR, NCO, (CH2)nCOOR, NHCOOR, -(CH2)n-OH, -NR(CH2)nNR2, C(OH)R2, -NR(CH2)nOR, NCOR, (CH2)narilo, (CH2)nheteroarilo, (CH2)nR1, (CH2)nX(CH2)narilo, (CH2)nX(CH2)nheteroarilo, (CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)nX-arilo, N[(CH2)nXR]SO2(CH2)narilo, N[(CH2)nNRCOOR]CO(CH2)narilo, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nNR2]CO(CH2)nNR-arilo, N[(CH2)nNR2]SO2(CH2)narilo, N[(CH2)nXR]CO(CH2)nheteroarilo, N[(CH2)nXR]CO(CH2)nX-heteroarilo, CO-arilo, SO2-heteroarilo, N[(CH2)nXR]SO2(CH2)nheteroarilo, N[(CH2)nNRCOOR]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nNR-heteroarilo, R1, y R3 conjuntamente también pueden significar -N-C(CF3)=N-, -N-CR=N-, -N-N=N-, y en donde los grupos no adyacentes CY2 también pueden estar reemplazados por X; Y es H, A, Hal, OR, E-R1; E es -NR1SO2-, -SO2NR1, -CONR1, -NR1CO-, -COO-, -OOC-, -CO-, -SO2-, - X-, -NR1CONR1, -OCONR1, -NR1COO-, -CSNR1, NR1CS-, -NR1CSNR1-, -SCONR1, -NR1COS-, -OCSNR1, NR1CSO-, -SCSNR1, -NR1CSS o un enlace simple; A es alquilo o cicloalquilo, donde uno o varios átomos de H pueden estar reemplazados por Hal; Hal es F, Cl, Br o I; R es H o A, en caso de radicales geminales también son juntos -(CH2)5-, -(CH2)4-, o -(CH2)n-X-(CH2)n, o -(CH2)n-Z-(CH2)n; R4, R4', R5, R5' son de modo independiente entre sí, H o N-pirrolidona no substituida o mono- o polisubstituida con OR, NO2, Hal, CF3, OCF3, CN, NR2, o SR, arilo o heteroarilo, Q, -(CY2)n-E-CR2R1, -(CY2)n-E-CR2XR1, -(CY2)n-E-(CY2)n-XR1 o -(CY2)n-E-(CY2)n-XRa, -X-(CH2)2OR, -X-CO(CH2)nCH3, -X-CO(CH2)2NR2, R1, S-arilo, O-arilo, CH2Si(CH3)3, o juntos son -X(CR2)2, -X-(CR2)3-, -X-CHQXY2-, -X-CH(CH2OR)(CY2)2-, -X-CH(CH2NR2)(CY2)2-, -X-CH=CQ-CH2-, -X-CQ=CH-CH2-, -X(CH2)2NR2, -(CR2)3-, -(CR2)4-, -CR=CR-CR=CR-, -XCHQ(CY2)2-, -XCHQCR2-, -R-N-(C=X)-N-R, -XC[(CH2)nOR]2CH2CH2-, -X-CY2CH(CH2OR)CY2, -XCY2CH(CH2NR2)CY2-, -X-CY2CHQ- CY2-, -XCHQCY2-, -XCY2CHQ-, -XCHQ(CY2)3-, -XCHQ(CY2)4-, -XCY2CHQ(CY2)2-, -XCY2CHQ(CY2)3-; X es O, S, o NR1; Q es (CH2)p-E-(CH2)pR1, (CH2)p-E-(CH2)pRa, (CH2)pHal, CHO, (CH2)pSR1, CORa, (CH2)pRa, (CH2)pOCORa, (CH2)pNCOR1, (CH2)pN(R1)2, (CH2)pOR1, (CH2)pOCON(R1)2, (CH2)pOCOOR1, (CH2)pNHCON(R1)2, (CH2)pNHCOOR1, (CH2)pCN, (CH2)pCOOR1, un resto seleccionado del grupo de formulas (2), OR, NHR, NR2, NR(CH2)narilo, NR(CH2)nOR, COOR, N-residuo de pirrolidona, OCOR, NR(CH2)nR2, (CY2)n-arilo, (CY2)2- heteroarilo, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nNHCOOR]CO-arilo, R1, N[CH2(CH2)nOR]2, NR(CH2)nNCOOR, X (CH2)nX(CH2)nXR, NR(CH2)nX(CH2)nOH, NR(CH2)nO(CH2)nOH, (CH2)nCOOR, O(CO)NR(CH2)nOR, O(CO)(CH2)nNR2, NR(CH2)nNR2, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nR1, N(R)(CH2)nN(R)COOR, XCOO(CH2)nNR2, OSO2A, OSO2CF3, OSO2Ar, OCONR2, OCH2(CH2)nNR2, CONR1, COR1; Z es CH2, X, CHCONH2, CH(CH2)nNR1COOR1, CHNR1COOR1, NCHO, CHCON(R1)2, CH(CH2)nCOOR1, NCOOR1, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nN(R1)2, C(OH)R1, CHNCOR1, NCOR1, N(CH2)narilo, N(CH2)nheteroarilo, CHR1, NR1, CH(CH2)narilo, CH(CH2)nheteroarilo, CH(CH2)nR1, N(CH2)nCOOR1, CH(CH2)nX(CH2)narilo, CH(CH2)nX(CH2)nheteroarilo, N(CH2)nCON(R1)2, NSO2R1, CHSO2N(R1)2, XCONR1(CH2)nN(R1)2, NCO(CH2)narilo, NCO(CH2)nXarilo, NSO2(CH2)narilo, NCO(CH2)nNR1arilo, NCO(CH2)nheteroarilo, NCO(CH2)nXheteroarilo, NSO2(CH2)nheteroarilo, NCO(CH2)nNR1heteroarilo, N(CH2)nNR2CH, CHO(CH2)nN(R1)2, CHX(CH2)nN(R1)2, NCO(CH2)nNR2, CHRa, NRa, C(OH)CY3, C(OH)arilo, C(NR2)arilo; R6 es arilo o héteroarilo no substituido o mono-, o polisubstituido con arilo o héteroarilo, que puede estar substituido con Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2, -(CY2)n-OR, -OCOR, -(CY2)n-CO2R, -(CY2)n-CN, -NCOR, -COR o -(CY2)n-NR2; R6' es H o R6; R7 es (C=O)-R, (C=O)-NR2, (C=O)-OR, H o A; m es 0, 1 o 2, y n es 0, 1, 2, 3, 4, 5, 6 o 7, p es 0, 1, 2, 3, 4 o 5, con preferencia 1 o 2; s es 0, 1, 2, 3, 4, 5, 6 o 7, en especial 0, así como sus derivados, solvatos, tautomeros, sales y estereoisomeros de utilidad farmacéutica, así como sus mezclas en todas las proporciones. Pueden ser utilizados, por ejemplo, para el tratamiento de tumores.
ARP060102412A 2005-06-13 2006-06-09 Tetrahidroquinolinas sustituidas AR054616A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005027170A DE102005027170A1 (de) 2005-06-13 2005-06-13 Substituierte Tetrahydrochinoline

Publications (1)

Publication Number Publication Date
AR054616A1 true AR054616A1 (es) 2007-07-04

Family

ID=36699028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102412A AR054616A1 (es) 2005-06-13 2006-06-09 Tetrahidroquinolinas sustituidas

Country Status (15)

Country Link
US (1) US7893082B2 (es)
EP (1) EP1891076B1 (es)
JP (1) JP5180070B2 (es)
KR (1) KR20080030015A (es)
CN (2) CN102010416A (es)
AR (1) AR054616A1 (es)
AU (1) AU2006312800B2 (es)
BR (1) BRPI0611613A2 (es)
CA (1) CA2611889C (es)
DE (1) DE102005027170A1 (es)
ES (1) ES2566729T3 (es)
MX (1) MX2007015782A (es)
RU (1) RU2007147925A (es)
WO (1) WO2007054138A1 (es)
ZA (1) ZA200800365B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102007013855A1 (de) * 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
WO2009052288A1 (en) 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
WO2009077052A2 (en) * 2007-12-18 2009-06-25 Merck Patent Gmbh Process for preparing tetrahydroquinoline derivatives
EP3703692A4 (en) * 2017-11-01 2021-04-28 Merck Sharp & Dohme Corp. NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
WO2022138888A1 (ja) 2020-12-25 2022-06-30 東レ株式会社 テトラヒドロキノリン誘導体及びその医薬用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027093A1 (en) * 1996-12-18 1998-06-25 Eli Lilly And Company Combinatorial process for preparing hydrofuroquinoline libraries
US6288075B1 (en) * 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
US7250423B2 (en) 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
WO2005016255A2 (en) * 2003-07-16 2005-02-24 Ligand Pharmaceuticals Incorporated Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
JP5237555B2 (ja) * 2003-12-20 2013-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−（ヘテロ）アリール置換テトラヒドロキノリン誘導体
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
BRPI0510365A (pt) * 2004-04-28 2007-11-06 Takeda Pharmaceutical composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
ES2537759T3 (es) * 2006-06-19 2015-06-11 Merck Patent Gmbh Compuestos enriquecidos enantioméricamente y proceso

Also Published As

Publication number Publication date
EP1891076A1 (de) 2008-02-27
KR20080030015A (ko) 2008-04-03
AU2006312800A1 (en) 2007-05-18
ES2566729T3 (es) 2016-04-15
AU2006312800B2 (en) 2011-08-25
CA2611889A1 (en) 2007-05-18
CN101198613A (zh) 2008-06-11
US20080194615A1 (en) 2008-08-14
CA2611889C (en) 2013-05-14
CN102010416A (zh) 2011-04-13
BRPI0611613A2 (pt) 2010-09-21
US7893082B2 (en) 2011-02-22
MX2007015782A (es) 2008-02-22
JP2008545803A (ja) 2008-12-18
DE102005027170A1 (de) 2006-12-14
ZA200800365B (en) 2009-05-27
WO2007054138A1 (de) 2007-05-18
EP1891076B1 (de) 2016-01-27
RU2007147925A (ru) 2009-07-20
JP5180070B2 (ja) 2013-04-10

Similar Documents

Publication Publication Date Title
AR054616A1 (es) Tetrahidroquinolinas sustituidas
AR054615A1 (es) Tetrahidroquinolinas
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
WO2008041053A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
DOP2007000022A (es) Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica
AR077598A1 (es) Compuestos heterociclicos fusionados como modulares de canales ionicos
AR077974A1 (es) Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor
AR052343A1 (es) Analogos de tetrahidroquinolina como agonistas muscarinicos
AR040514A1 (es) Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin
AR049701A1 (es) Aminas terciarias no imidazolicas que actuan como inhibidores del receptor de histamina 3 para el tratamiento de trastornos cognitivos y del sueno, obesidad y otros trastornos del snc
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR063800A1 (es) Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos
AR069804A1 (es) Agonistas del receptor glucocorticoide c20- c21 sustituido
SV2010003459A (es) Derivados de pirimidina 934
AR083635A1 (es) Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales
AR054282A1 (es) Derivados de tetrahidroquinolina
AR059886A1 (es) Derivados de amidas como inhibidores de renina
AR065891A1 (es) Derivados de piridina y pirimidina como antagonistas del mglur2
AR075920A1 (es) Derivados de nicotinamida su preparacion y su aplicacion en terapeutica
AR108175A1 (es) Compuestos antivíricos de tiazol acetamida
AR058397A1 (es) Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR050153A1 (es) Beta-agonistas, procedimiento para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal